168 related articles for article (PubMed ID: 15569162)
1. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN
Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162
[TBL] [Abstract][Full Text] [Related]
2. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V
Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
[TBL] [Abstract][Full Text] [Related]
3. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
4. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
DiMichele DM; Lasak ME; Miller CH
Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
Bidlingmaier C; Deml MM; Kurnik K
Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
[TBL] [Abstract][Full Text] [Related]
6. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
7. Lyophilized cryoprecipitate for children with hemophilia A.
Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII.
Takedani H
Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072
[TBL] [Abstract][Full Text] [Related]
9. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
Fernandez M; Yu T; Bjornson E; Luu H; Spotts G
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors.
Kasuda S; Tanaka I; Shima M; Matsumoto T; Sakurai Y; Nishiya K; Giles AR; Yoshioka A
Haemophilia; 2004 Jul; 10(4):341-6. PubMed ID: 15230947
[TBL] [Abstract][Full Text] [Related]
11. Infection risk and stability of a continuous 8-h 250 mL rFVIII infusion.
Lambing A; Kuriakose P; Mueller LM
Haemophilia; 2014 Mar; 20(2):212-8. PubMed ID: 24251950
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
[TBL] [Abstract][Full Text] [Related]
13. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of factor VIII for surgery and major bleeding.
Hay CR; Doughty HI; Savidge GF
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
18. [The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump].
Rodríguez Bueno S; Montoro Ronsano JB; Martínez Sánchez B; Altisent Roca C; Tusell Puigvert JM
Med Clin (Barc); 1991 Mar; 96(10):364-6. PubMed ID: 1904520
[TBL] [Abstract][Full Text] [Related]
19. Cryoprecipitate-removed plasma 'cryo-removed plasma' as a source of factor IX in the treatment of haemophilia B.
Lepatan LM; Hernandez FG; Montoya MM; Ong JB; Rodriguez EV; Chua MN
Haemophilia; 2004 May; 10(3):254-8. PubMed ID: 15086323
[TBL] [Abstract][Full Text] [Related]
20. Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease.
Mathews V; Srivastava A; Nair SC; Chandy M
Natl Med J India; 2000; 13(4):188-90. PubMed ID: 11002685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
